One Case of Thyroid and Cardiac Damage Caused by Tislelizumab Injection

doi:10.19803/j.1672-8629.20250295

Abstract

Abstract: Objective To investigate such serious adverse reactions as thyroid and cardiac damage induced by tislelizumab in order to provide a reference for safe medications. Methods One case of thyroid and cardiac damage in a patient with cholangiocarcinoma liver metastasis after 10 cycles of treatment with tislelizumab injection in combination with gemcitabine and capecitabine was discussed. The clinical features and treatment of adverse reactions based on related literature were reviewed. Results Based on the patient’s medical history, medication history, drug prescriptions and literature, this event was assessed as an immune-related adverse reaction caused by tislelizumab, manifested as a series of severe adverse reactions, such as hypothyroidism, cardiac damage, heart failure, and ventricular fibrillation. After anti-inflammatory, anti-heart failure and anti-arrhythmia treatments and thyroid hormone supplementation, the patient’s thyroid function and cardiac function improved significantly. Conclusion Clinicians should be alert to the potential risk of thyroid and myocardial damage induced by tislelizumab so as to prevent deadly serious adverse reactions and ensure the safety of medication.

Key words: Tislelizumab, Hypothyroidism, Heart Failure, Ventricular Fibrillation, Serious Adverse Reaction, Immune-Related Adverse Events (irAEs)

CLC Number:

ZHANG Jing, YANG Bo, YANG Shuai, MAO Meijuan, YAO Jingyue, GUO Qing. One Case of Thyroid and Cardiac Damage Caused by Tislelizumab Injection[J]. Chinese Journal of Pharmacovigilance, 2026, 23(3): 343-345.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.20250295

https://zgywjj.magtechjournal.com/EN/Y2026/V23/I3/343

References

[1] Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology Management of Immune Checkpoint Inhibitor-Related Toxicity 2023
(中国临床肿瘤学会CSCO免疫检查点抑制剂相关的毒性管理指南2023)[M]中国临床肿瘤学会CSCO免疫检查点抑制剂相关的毒性管理指南2023)[M]. Beijing: People’s Medical Publishing House, 2023.
[2] DE CAMILLI A, FISCHER G.Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications[J]. Current Oncology, 2023, 30(8): 7638-7653.
[3] ZHAO P, ZHAO T, YU L, et al.The Risk of Endocrine Immune-Related Adverse Events Induced by PD-1 Inhibitors in Cancer Patients: a Systematic Review and Meta-Analysis[J]. Frontiers in Oncology, 2024, 14: 1381250.
[4] DENG C, YANG M, JIANG H, et al.Immune-Related Multiple-Organs Injuries Following ICI Treatment with Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: a Case Report[J]. Frontiers in Oncology, 2021, 11: 664809.
[5] HU X, WEI Y, SHUAI X.Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient with ICI-Associated Myocarditis and Multiple Organ Injuries[J]. Frontiers in Immunology, 2021, 12: 799077.
[6] YUAN M, HAN N, SHU L, et al.Case Report: Multi-Organ Injuries Induced by Tislelizumab[J]. Frontiers in Immunology, 2025, 16: 1508293.
[7] ZHANG J, ZHANG LL, LI X.Immune-Related Adverse Events of Tirelizumab in 424 Cases of Cancer Patients[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(4): 435-446.
[8] WANG Y, HUANG S, SHEN QY, et al.Seventy-Nine Cases of Tislelizumab-Related Adverse Reactions[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2024, 21(10): 1148-1153.
[9] SONG QY, TAI QR, ZHANG BK, et al.A Case Report of Immune-Related Multisystem Adverse Reactions Caused by Tislelizumab[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2025, 34(3): 359-364.
[10] TING Y, MINGHUI L, CHAOYI L, et al.Immune-Related Adverse Events with PD-1/PD-L1 Inhibitors: Insights from a Real-World Cohort of 2523 Patients[J]. Frontiers in Pharmacology, 2025, 16: 1519082.
[11] ZHU H, GALDOS FX, LEE D, et al.Identification of Pathogenic Immune Cell Subsets Associated with Checkpoint Inhibitor-Induced Myocarditis[J]. Circulation, 2022, 146(4): 316-335.
[12] KARAVITI D, KANI ER, KARAVITI E, et al.Thyroid Disorders Induced by Immune Checkpoint Inhibitors[J]. Endocrine, 2024, 85(1): 67-79.
[13] NARANJO CA, BUSTO U, SELLERS EM, et al.A Method for Estimating the Probability of Adverse Drug Reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[14] HUSEBYE ES, CASTINETTI F, CRISENO S, et al.Endocrine-Related Adverse Conditions in Patients Receiving Immune Checkpoint Inhibition: an ESE Clinical Practice Guideline[J]. Eur J Endocrinol, 2022, 187(6): G1-G21.
[15] HAANEN J, OBEID M, SPAIN L, et al.Management of Toxicities from Immunotherapy: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up[J]. Ann Oncol, 2022, 33(12): 1217-1238.
[16] The Joint Committee of Cardiomyopathy Specialty Alliance, National Center for Cardiovascular Diseases; Cardiovascular Precision Medicine Branch of China International Exchange and Promotive Association for Medical and Health Care. 2024 Guideline for Diagnosis and Treatment of Adult Patients with Myocarditis[J]. Chinese Circulation Journal(中国循环杂志), 2024, 9(6): 521-536.
[17] DRAZNER MH, BOZKURT B, COOPER LT, et al.2024 ACC Expert Consensus Decision Pathway on Strategies and Criteria for the Diagnosis and Management of Myocarditis: a Report of the American College of Cardiology Solution Set Oversight Committee[J]. Journal of the American College of Cardiology, 2025, 4(85): 391-431.
[18] Society of Integrative Cardio-Oncology China Anti-Cancer Association, The Cardio-Oncology Group of the Chinese Society of Cardiovascular Diseases of Chinese Medical Association, Chinese College of Cardio-vascular Physicians Specialized Committee on Cardio-Oncology Chinese Medical Doctor Association, et al. Chinese Expert Consensus on the Surveillance and Management of Immune Checkpoint Inhibitor-Related Myocarditis(2020 Version)[J]. Chinese Journal of Clinical Oncology(中国肿瘤临床), 2020, 47(20): 1027-1038.